sinha et al 2018 liposomal glutathione and neurodegenerative diseases: immunopharmacological implications Shoutout alert! ✨ Pure Encapsulations®

In patients with severe hepatic or renal disease, effects of therapy should be followed with serial liver and/or renal function tests Inhibitors of CYP3A4 and CYP2D6 The concomitant use of Hydrocodone Bitartrate and Acetaminophen Tablets and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g

This pertains for instance to the updated OECD guideline for 28-day oral toxicity testing (Koeter, 1995)

10.1113/JP276626 110 KuhnS

Preclinical and clinical trials should be designed accordingly, with a focus on conditions where antioxidant therapy is more likely to yield therapeutic benefit